1 Sanders ME. Probiotics: Considerations for human health. Nutr Rev. 2003;61(3):91-99.

2 Saarela M, et al. Safety aspects of Lactobacillus and Bifidobacterium species originating from human gastrointestinal tract or from probiotic products. Microb Ecol Health Dis. 2002;14:233-240.

3 Borriello et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36(6):775-780.

4 Horowitz S. Promoting gut health with probiotics. Living medicines for treating digestive disorders. Altern Complement Ther. 2003;9(5):219-224.

5 Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: Composition and succession. Curr Issues Intest Microbiol. 2001;2(2):43-53

6 Mountzouris K, et al. Intestinal microflora of human infants and current trends for its nutritional modulation. Br J Nutr. 2002;87(5):405-420.

7 Holzapfel WH, et al. Overview of gut flora and probiotics. Int J Food Microbiol. 1998;41(2):85-101

8 McNaught CE, et al. Probiotics in clinical practice: A critical review of the evidence. Nutr Res. 2001;21(1&2):343-353

9 Heller F, et al. Intestinal flora and mucosal immune responses. Int J Med Microbiol. 2003;293(1):77-86

10 Fabia R, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion.

11 Shaw K, et al. Dysbiosis, inflammation, and response to treatment a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome Medicine. 2016; 8-75

12 Bullock, et al. Comparative composition of bacteria in the human intestinal microflora during remission and active ulcerative colitis. Curr Issues Intest Microbiol. 2004;5:59-64.

13 Balsari, et al. The faecal microbial population in the irritable bowel syndrome. Microbiologica. 1982;5(3):185-194.

14 Madden and Hunter. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr. 2002;88 (Suppl.1):S67-S72.

15 Malinen, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and health controls with real-time PCR. Am J Gastroenterol. 2005;100(2):373-82.

16 Haque T, et al. Intestinal microbiota in liver disease. Best Practice & Research Clinical Gastroenterology 30 (2016) 133-142

17 Rai R, et al. Gut Microbiota: Its Role in Hepatic Encephalopathy. Journal of Clinical and Experiential Hepatology. 2015 Mar;5(Suppl 1):S29-36.

18 Bajaj et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012 Jan; 302(1) G168–G175.

19 Mimemura and Shimizu. Gut microbiota and liver disease. World J Gastroenterol. 2015 Feb 14 21(6) 1691-1702

20 Sung et al. Microbiota-based treatments in alcoholic liver disease. World J Gastroenterol 2016 August 7 22(29) 6673-6682

21 Llorente C and Schbabl B. The Gut Microbiota and Liver Disease. Cell Mol Gastroenterol Hepatol 2015 1 275-284

22 Kim et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil (2005) 17,1-10

23 Kim et al. A randomized controlled trial of a probiotic, VSL#3, on gut transitand symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:895-904

24 Chio et al. Alteration of Gut Microbiotia and Efficacy of Probiotics in Functional Constipation. J Neurogastroenterol Motil. Vol. 21 2093-0879 2015

25 Wong et al. Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study. Dig Dis Sci. 2014

26 Bibiloni et al. VSL#3* Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. Am J Gastroenterology 2005;100:1539-1546

27 Tursi A, et al. Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to- moderate ulcerative colitis. Med Sci Monit. 2004;10:126-131.

28 Huynh et al. Probiotic Preparation VSL#3* Induces Remission in Children with Mild to Moderate Acute Ulcerative Colitis: A Pilot Study. Inflam Bowel Dis. 2008

29 Sood et al. The Probiotic Preparation, VSL#3* Induces Remission in Patients with Mild to Moderately Active Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2009;7:1202-1209

30 Tursi, et al. Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL # 3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. American Journal Of Gastro. 2010

31 Gionchetti P, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305-309.

32 Gionchetti P, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology. 2003b;124(5):1202-1209.

33 Mimura et al. Once daily high dose probiotic therapy (VSL#3*) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114

34 Kornbluth, et al. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Committee. Am J Gastroenterol. 2010; Mar;105(3):501-23.

35 Hoffmann JC, et al. Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German Society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease. Z Gastroenterol. 2004;42:979-983.

36 Mowat C, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011. May 60(5) 571-607

37 Biancone L, et al. European evidence-based Consensus on the management of ulcerative colitis: Special situations. J. Crohns Colitis. (2008) 2, 63-92

38 Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis (Review). Cochrane Database of Systematic Reviews. 2010, Issue 6. Art. No.: CD001176. DOI: 10.1002/14651858.CD001176. pub2.

39 Dhiman et al. Probiotic VSL#3* Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized Controlled Trial. Gastroenterology. 2014;147:1327-1337

40 Agrawal A. et al., Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No Therapy. American Journal of Gastroenterology. 2012

41 Mittal, V.V. et al, A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology and Hepatology. 2011

42 Lunia MK, et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol. 2014 Jun;12(6):1003- 8

43 Misra, et al. Integrative Therapies and Pediatric Inflammatory Bowel Disease: The Current Evidence. Children 2014, 1, 149-165.

44 Guandalini et al. VSL#3 Improves Symptoms in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Crossover Study. JPNG. 2010;51: 24-30